Abstract
An early discrimination of survival probability is required for patients with diffuse large B cell lymphoma (DLBCL), which may identify patients that require other treatment options, for example clinical trials. To the best of our knowledge, the impact of interim evaluation with 18fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) has not yet been determined in this type of neoplasia. The aim of the present study was to determine the role of changes in metabolic tumor volume (MTV) between baseline and interim 18F-FDG PET/CT scans, following three courses of chemotherapy in order to predict complete response (CR) and overall survival (OS) in patients with DLBCL. Patients with previously untreated DLBCL who had received the standard 6-8 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone were included in the present study. A predictive model was constructed using changes in MTV and other clinical factors including age, gender, East Cooperative Oncology Group (ECOG) status, clinical stage, B symptoms, the presence of bulky disease and elevated lactate dehydrogenase levels, and data were analyzed using logistic regression analysis. In total, 50 patients with DLBCL were in...Continue Reading
References
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Feb 26, 2003·European Journal of Nuclear Medicine and Molecular Imaging·Karoline SpaepenChristine De Wolf-Peeters
Nov 16, 2006·Blood·Laurie H SehnJoseph M Connors
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malik E JuweidUNKNOWN Imaging Subcommittee of International Harmonization Project in Lymphoma
Mar 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teruhiko TerasawaHirokazu Nagai
Mar 18, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Emmanuel IttiMichel Meignan
Jun 23, 2009·Leukemia & Lymphoma·Michel MeignanCorinne Haioun
Oct 30, 2009·Leukemia & Lymphoma·Ulrich DührsenStefan Müller
Mar 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Craig H MoskowitzAndrew D Zelenetz
Nov 17, 2010·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Emmanuel IttiMichel Meignan
Feb 16, 2011·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Amanda F CashenNancy L Bartlett
Aug 19, 2011·Leukemia & Lymphoma·M Christina CoxM Antonietta Aloe Spiriti
Dec 14, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Violaine SafarCorinne Haioun
Jun 26, 2012·American Journal of Hematology·Silvia ParkWon Seog Kim
Dec 15, 2012·Annals of Hematology·Deok-Hwan YangJe-Jung Lee
Jan 25, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Silvia FuertesFrancesca Pons
Jan 17, 2014·European Journal of Haematology·Rosj GallicchioGiovanni Storto
Aug 13, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonT Andrew Lister
Sep 6, 2014·Journal of the National Comprehensive Cancer Network : JNCCN·Andrew D ZelenetzUNKNOWN National comprehensive cancer network
Jun 10, 2015·Cancer Causes & Control : CCC·Adam J OlszewskiJorge J Castillo
Jan 7, 2016·Clinical Radiology·S H KwonY-S An
Aug 25, 2016·Salud pública de México·Myrna Candelaria
Aug 12, 2017·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Sally F Barrington, Peter W M Johnson